Key statistics
On Thursday, ACELYRIN Inc (SLRN:NSQ) closed at 4.33, 28.87% above the 52 week low of 3.36 set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.26 |
---|---|
High | 4.51 |
Low | 4.24 |
Bid | 3.41 |
Offer | 5.89 |
Previous close | 4.43 |
Average volume | 499.05k |
---|---|
Shares outstanding | 99.81m |
Free float | 85.01m |
P/E (TTM) | -- |
Market cap | 432.17m USD |
EPS (TTM) | -2.68 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
- ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
- ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
- ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
- ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
- ACELYRIN, INC. to Participate in Upcoming Investor Conferences
- ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
- ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
- ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
- ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
More ▼